This post was originally published on this site
Cryoport (NASDAQ:CYRX) fell 24% in after-hours trading following the report.
The company said it now expects annual revenue in a range of $233 million to $243M, down from a prior range of $270M to $290M.
The weaker outlook comes as the company estimated second-quarter revenue to be between $56.5M and $57.5M for the second quarter of 2023. That was short of Wall Street estimates of $67M, with the company flagging several factors that pressured growth including “weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clients.”
